Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Mallinckrodt
Dow
Boehringer Ingelheim
McKinsey

Last Updated: January 27, 2023

Details for Patent: 7,736,665


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 7,736,665 protect, and when does it expire?

Patent 7,736,665 protects PROBUPHINE and is included in one NDA.

This patent has sixteen patent family members in thirteen countries.

Summary for Patent: 7,736,665
Title:Implantable polymeric device for sustained release of buprenorphine
Abstract: The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.
Inventor(s): Patel; Rajesh A. (Redwood City, CA), Bucalo; Louis R. (Miami Beach, FL)
Assignee: Titan Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:10/453,377
Patent Claim Types:
see list of patent claims
Use; Device;

Drugs Protected by US Patent 7,736,665

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Titan Pharms PROBUPHINE buprenorphine hydrochloride IMPLANT;IMPLANTATION 204442-001 May 26, 2016 DISCN Yes No See Plans and Pricing See Plans and Pricing FOR OPIOID DEPENDENCE See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,736,665

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003240493 See Plans and Pricing
Australia 2008212011 See Plans and Pricing
Canada 2487577 See Plans and Pricing
Cyprus 1120510 See Plans and Pricing
Denmark 2561860 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Baxter
Mallinckrodt
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.